MOTS-c

At a glance

Standard Protocol

Alternative: Endurance Athletes

Alternative Titration 2

Alternative Titration 3

Alternative Titration 4

Energy protocols are usually about mitochondrial or metabolic signaling. The logic is timing around meals/training, avoiding late-day stimulation, and watching sleep, glucose, blood pressure, and overtraining signals. Entry context: target (AMPK); route Subcutaneous; timing Pre-Workout. Unapproved or source-dataset dosing tables are hypotheses, not recommendations. FDA/safety flags lower confidence and raise the evidence bar for any claimed benefit.

• Hypoglycemia when dosed fasted without exercise: the most practically significant adverse effect; AMPK activation drives aggressive glucose uptake and fatty acid oxidation in muscle; without the energy demand of physical activity, blood glucose can drop significantly; always dose pre-workout, never fasted without planned exercise.
• Injection site reactions: redness, soreness, itching at subcutaneous site; the most commonly reported adverse effect in research and anecdotal use.
• Transient fatigue and flu-like symptoms in the first days of use: as the metabolic programs are initially activated; typically resolves within the first week.
• Mild flushing: sensation of warmth; related to increased metabolic rate and peripheral vasodilation from improved tissue perfusion.
• Gastrointestinal disturbances: mild nausea, diarrhea reported in a small subset of research subjects; usually early-cycle.
• Headache: mild; uncommon; mechanism not characterized.
• Potential AMPK overstimulation: theoretical; excessive AMPK activation suppresses mTOR signaling, which while broadly pro-longevity, may impair muscle protein synthesis recovery after intense training if MOTS-c is dosed immediately post-workout.
• No hormonal side effects: MOTS-c has no known activity at androgen, estrogen, or GH axis receptors.
• Injection site infection risk from non-sterile research chemical sourcing: an acknowledged risk with all unregulated research peptides; sterile technique is paramount.

• Severe cardiovascular disease or unstable cardiac conditions: MOTS-c's AMPK activation drives an intense metabolic demand similar to vigorous exercise; subjects unable to tolerate the cardiovascular load of physical exertion should not use MOTS-c.
• Active malignancy: AMPK pathway activation has complex effects on cancer cell metabolism; MOTS-c's nuclear translocation and gene regulatory activity in cancer cells is not characterized; use in active cancer is not established.
• Insulin therapy or sulfonylurea use without clinical supervision: MOTS-c activates GLUT4 expression and increases muscle glucose uptake via AMPK, which combined with exogenous insulin or insulin secretagogues creates a meaningful additive hypoglycemia risk.
• Metformin use: metformin also activates AMPK (through complex I inhibition); overlapping AMPK stimulation effects are not characterized; monitor blood glucose closely if combining.
• Beta-blocker therapy: beta-blockers mask the adrenergic warning signs (tachycardia, tremor) of hypoglycemia; in conjunction with MOTS-c's glucose-lowering AMPK activity, this is a meaningful safety concern.
• Pregnancy: MOTS-c modulates mitochondrial gene expression; safety during fetal development is entirely unknown.
• Breastfeeding: no data.
• Pediatric use: no safety or developmental data established.
• Known hypersensitivity to MOTS-c or peptide excipients.
• Athletes competing under WADA anti-doping regulations: MOTS-c is on the WADA Prohibited List.

Synergistic / related

• https://the source dataset.com/peptide-codex.php
• https://www.fda.gov/drugs/guidance-compliance-regulatory-information/human-drug-compounding
• https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks?pg=3
• https://pubmed.ncbi.nlm.nih.gov/?term=MOTS-c